Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim announces PRoFESS results at stroke meeting

Boehringer Ingelheim announces PRoFESS results at stroke meeting

19th May 2008

Boehringer Ingelheim has announced the results from the PRoFESS study, largest-ever stroke prevention trial, at the European Stroke Conference in Nice, France.

In the placebo-controlled trial, patients received either Aggrenox (extended-release dipyridamole) plus ASA, or clopidogrel and simultaneous randomisation to Micardis (telmisartan), or placebo.

The primary outcome recorded by the trial was first recurrent stroke with a pre-specified non-inferiority margin, with the rates of first recurrent stroke similar for both treatments over an average observation time of 2.5 years.

Professor Hans-Christoph Diener of the University of Essen, Germany, said: “Given the high prevalence of stroke and recurrent stroke in ageing societies, physicians need a range of treatment options so they can offer patients a regimen tailored to their individual needs.”

He added that trials such as PRoFESS help clinicians make evidence-based treatment choices, thus ensuring that patients receive the best therapy.

Professor Ralph L Sacco of the Department of Neurology at the University of Miami, Florida, said the scientific community gained valuable information regarding different therapeutic options during the study.

In April 2008, Boehringer Ingelheim announced the results of the Ontarget study showing that Micardis (telmisartan) is as effective as ramipril in reducing the risk of stroke and various heart conditions.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.